These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

587 related items for PubMed ID: 8242227

  • 1. Differential class III and glibenclamide effects on action potential duration in guinea-pig papillary muscle during normoxia and hypoxia/ischaemia.
    MacKenzie I, Saville VL, Waterfall JF.
    Br J Pharmacol; 1993 Oct; 110(2):531-8. PubMed ID: 8242227
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Electrophysiological effects of EGIS-7229, a new antiarrhythmic agent, in isolated mammalian and human cardiac tissues.
    Pankucsi C, Bányász T, Magyar J, Gyönös I, Kovács A, Varró A, Szénási G, Nánási PP.
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Mar; 355(3):398-405. PubMed ID: 9089672
    [Abstract] [Full Text] [Related]

  • 5. Class I antiarrhythmic drugs alter the severity of myocardial stunning by modulating ATP-sensitive K+ channels in guinea pig ventricular muscles.
    Shigematsu S, Sato T, Arita M.
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Mar; 357(3):283-90. PubMed ID: 9550300
    [Abstract] [Full Text] [Related]

  • 6. Differential rate and potassium-dependent effects of the class III agents d-sotalol and dofetilide on guinea pig papillary muscle.
    Marschang H, Beyer T, Karolyi L, Kübler W, Brachmann J.
    Cardiovasc Drugs Ther; 1998 Dec; 12(6):573-83. PubMed ID: 10410827
    [Abstract] [Full Text] [Related]

  • 7. Electrophysiological effects of CI-980, a tubulin binding agent, on guinea-pig papillary muscles.
    Pérez O, Valenzuela C, Delpón E, Tamargo J.
    Br J Pharmacol; 1997 Jan; 120(2):187-92. PubMed ID: 9117108
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Interaction of the effects of hypoxia, substrate depletion, acidosis and hyperkalaemia on the class III antiarrhythmic properties of sotalol.
    Cobbe SM, Manley BS, Alexopoulos D.
    Cardiovasc Res; 1985 Nov; 19(11):668-73. PubMed ID: 4075356
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Attenuation by phentolamine of hypoxia and levcromakalim-induced abbreviation of the cardiac action potential.
    Tweedie D, Boachie-Anash G, Henderson CG, Kane KA.
    Br J Pharmacol; 1993 Nov; 110(3):1222-6. PubMed ID: 8298812
    [Abstract] [Full Text] [Related]

  • 17. Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes.
    Nakaya H, Tohse N, Takeda Y, Kanno M.
    Br J Pharmacol; 1993 May; 109(1):157-63. PubMed ID: 7684298
    [Abstract] [Full Text] [Related]

  • 18. Mexiletine-induced shortening of the action potential duration of ventricular muscles by activation of ATP-sensitive K+ channels.
    Sato T, Shigematsu S, Arita M.
    Br J Pharmacol; 1995 Jun; 115(3):381-2. PubMed ID: 7582444
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the cardiac electrophysiologic effects of NE-10064 with sotalol and E-4031 and their modification by simulated ischaemia.
    McIntosh MA, Tanira M, Pacini D, Kane KA.
    J Cardiovasc Pharmacol; 1994 Apr; 23(4):653-7. PubMed ID: 7516018
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.